PMID- 2976829
OWN - NLM
STAT- MEDLINE
DCOM- 19890502
LR  - 20191022
IS  - 0165-0378 (Print)
IS  - 0165-0378 (Linking)
VI  - 14
IP  - 2
DP  - 1988 Nov
TI  - Immunological studies in recurrent spontaneous abortion: effects of immunization 
      of women with paternal mononuclear cells on lymphocytotoxic and mixed lymphocyte 
      reaction blocking antibodies and correlation with sharing of HLA and pregnancy 
      outcome.
PG  - 99-113
AB  - The occurrence of maternal antipaternal lymphocytotoxic antibody (LCTA), mixed 
      lymphocyte reaction blocking factors (MLRBF) and human leukocyte antigen (HLA) 
      antigen sharing was studied in 115 couples with unexplained repeated spontaneous 
      abortions (RSA). Comparisons were made to the same studies done on 41 couples 
      with explained repeated miscarriages. We found no significant difference between 
      the patient and control group with respect to the percent of couples sharing 
      none, one, or two or more HLA-A,-B, or -DR antigens. Examination of the 
      occurrence of LCTA and MLRBF likewise did not reveal differences between the 
      groups, nor did the occurrence of these antibodies on initial testing correlate 
      with HLA disparity between couples. Women with three or more spontaneous 
      abortions were immunized with paternal mononuclear cells (MNC) if they met at 
      least two of the following three criteria: they shared two or more HLA antigens; 
      their serum was negative for paternal MNC-directed LCTA; their serum did not 
      contain maternal versus paternal MLR blocking factors. Complete HLA, LCTA and 
      MLRBF data pre- and post-treatment are available on 60 women. Sixty-three percent 
      of women converted to LCTA positive 6 +/- 1 weeks after immunization, and 35% of 
      women converted from negative to positive for MLR blocking after immunization. 
      Fifty-eight women who had all three tests done prior to immunization became 
      pregnant after immunization. Only 50% of this selected group have experienced 
      successful pregnancy as judged by delivery of a live-born infant. In the patients 
      presented, successful pregnancy outcome did not correlate with HLA antigen 
      disparity, but successful patients were more likely than aborters to have either 
      LCTA or MLRBF prior to pregnancy (28 vs. 7%). Post-immunization conversion to 
      LCTA positive was more prevalent in the women who aborted after immunization 
      (74%) compared to those who had successful pregnancy (48%) while MLR blocking 
      antibody conversion from negative to positive was the same in both groups. The 
      data indicate that neither HLA antigen sharing nor conversion to LCTA or MLR 
      blocking positive after paternal WBC immunization are predictors for successful 
      pregnancy outcome. Results so far suggest that conversion to LCTA positive after 
      immunization may have a negative influence on pregnancy outcome.
FAU - Smith, J B
AU  - Smith JB
AD  - Department of Medicine, Jefferson Medical College, Thomas Jefferson University, 
      Philadelphia, PA 19107.
FAU - Cowchock, F S
AU  - Cowchock FS
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - J Reprod Immunol
JT  - Journal of reproductive immunology
JID - 8001906
RN  - 0 (Antibodies)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Abortion, Habitual/*immunology/prevention & control
MH  - Antibodies/immunology
MH  - Cytotoxicity Tests, Immunologic
MH  - Female
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Immunization/*methods
MH  - Leukocytes, Mononuclear/*immunology
MH  - Lymphocyte Culture Test, Mixed
MH  - Male
MH  - Pregnancy
MH  - *Pregnancy Outcome
MH  - Pregnancy Tests, Immunologic
MH  - T-Lymphocytes, Cytotoxic/*immunology
EDAT- 1988/11/01 00:00
MHDA- 1988/11/01 00:01
CRDT- 1988/11/01 00:00
PHST- 1988/11/01 00:00 [pubmed]
PHST- 1988/11/01 00:01 [medline]
PHST- 1988/11/01 00:00 [entrez]
AID - 0165-0378(88)90062-9 [pii]
AID - 10.1016/0165-0378(88)90062-9 [doi]
PST - ppublish
SO  - J Reprod Immunol. 1988 Nov;14(2):99-113. doi: 10.1016/0165-0378(88)90062-9.